Savara shares are crushed as PhIII trial flunks primary, key secondaries — but they can’t stop believing
Investors are in no mood to hear biotechs tout the success of a “key” secondary endpoint when the pivotal Phase III flunks the primary goal. Just ask Savara.
The Texas biotech $SVRA went looking for a silver lining as company execs bluntly conceded that Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), failed to spur significantly improved treatment outcomes for patients with a rare respiratory disease called autoimmune pulmonary alveolar proteinosis, or aPAP.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.